Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
The New York Stock Exchange (NYSE) has commenced proceedings to delist Elme Communities' common shares and immediately suspended trading due to abnormally low selling price levels. The company does not intend to appeal the decision as it is already executing a previously approved Plan of Sale and Liquidation. Elme anticipates its shares will begin trading over-the-counter (OTC) under the symbol 'ELMES' on October 26, 2026.
ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted antibody-drug conjugate ARR-217 in patients with gastrointestinal cancers, reporting a 44.8% objective response rate at the 6mg/kg dose in late-line colorectal cancer patients. The study, conducted in partnership with Lepu Biopharma, showed a manageable safety profile and has advanced into Phase 1b dose optimization with further data expected in 2027.
Counterparty
Lepu Biopharma Co., Ltd.
“These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
“We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
Eikon Therapeutics presented updated Phase 1b data from its TeLuRide-005 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for advanced NSCLC at the 2026 ESMO Congress. The trial demonstrated a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) across the pooled population, with a safety profile supportive of outpatient administration. The squamous cohort specifically showed a 72.4% ORR and 100% DCR with a median duration of response of 12.9 months.
Cyber Enviro-Tech, Inc. entered into Amendment No. 2 to its existing Equity Purchase Agreement with Monroe Street Capital Partners, LP, which allows the company to sell up to $30 million of common stock. The amendment modifies the pricing mechanism for 'put notices' to be based on the end-of-day volume-weighted average price (EOD VWAP) rather than the lowest traded price, while maintaining a 15% discount factor. The company also disclosed a prior amendment that reduced the minimum put amount to facilitate easier access to the capital facility.
Charlton Aria Acquisition Corp notified Nasdaq that it failed to satisfy audit committee independence requirements due to a compensatory payment made to a firm associated with director Kyoung Tak Kim. The company regained compliance on October 22, 2026, by removing Mr. Kim from the audit committee and appointing Wang Jo Cha as his replacement.
Innventure, Inc. received a deficiency notice from Nasdaq on October 23, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has until April 21, 2027, to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business days. If compliance is not met, the company may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market.
Climb Bio and Mabworks announced additional Phase 1 clinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrating deep and durable APRIL suppression through 12 weeks. The data showed a 33-day half-life and a 70% reduction in Gd-IgA1 at 12 weeks, supporting a potential every-12-week dosing regimen. The company remains on track to report initial Phase 2 data in the first half of 2027 and plans to initiate a global Phase 3 trial in 2027.
22nd Century Group filed a prospectus supplement to sell up to $18.8 million in common stock through an at-the-market (ATM) offering program. The company disclosed that during October 2026, it sold approximately 15.79 million shares, raising gross proceeds of approximately $4.7 million.
Traws Pharma entered into a common stock purchase agreement with Roth Principal Investments for an equity line of credit of up to $50 million. The company has the right, but not the obligation, to sell shares to Roth over a 36-month period following the effectiveness of a registration statement. This facility provides the company with flexible access to capital to fund operations at its sole discretion.
Proficient Auto Logistics M&A Deal with Hansen & Adkins Auto Transport, LLC
Proficient Auto Logistics, Inc. (PAL) completed its acquisition of the Hansen & Adkins group of companies, including H&A Auto Transport, H&A Auto Logistics, Royal Truck Leasing, and H&A Canada. This filing serves as an amendment to provide the required audited and pro forma financial statements for the acquired businesses following the closing on August 13, 2026.
Medicus Pharma Ltd. regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common shares closed at or above $1.00 for ten consecutive business days. This compliance notice supersedes a delisting determination letter received on October 20, 2026, which had initially triggered a delisting process due to the company's failure to meet the bid price and stockholders' equity requirements.
Silver Bow Mining M&A Deal with Montana Goldfields, Inc. and Montana Tunnels Mining, Inc.
Silver Bow Mining Corp. entered into an amendment to its existing asset purchase agreement with Montana Goldfields and Montana Tunnels Mining to update the deal timeline. The amendment extends the 'Outside Date' for the transaction to 60 days following the delivery of audited financial statements and sets a target date of October 31, 2026, for the sellers to produce those financials.
Counterparty
Montana Goldfields, Inc. and Montana Tunnels Mining, Inc.
Alpine Income Property Trust, Inc. announced a preferred stock offering of 189,747 additional shares of its 8.00% Series A Cumulative Redeemable Preferred Stock. In connection with the offering, the company's manager agreed to waive 50% of the base management fee attributable to the new equity proceeds, reducing the fee rate from 1.50% to 0.75% per annum on that capital.
Transocean Ltd. provided a status update on its pending acquisition of Valaris Limited, announcing that the Bermuda Court sanction hearing is scheduled for November 26, 2026. If sanctioned, the company anticipates the business combination will be consummated on or about December 1, 2026, following shareholder meetings on November 24, 2026.
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc clinical trial evaluating oral ifetroban in patients with systemic sclerosis. The study results supported the safety and tolerability of the drug candidate in this rare disease population.
Valaris Limited provided a status update on its pending merger with Transocean Ltd., announcing that the Bermuda Court sanction hearing is scheduled for November 26, 2026. If the court sanctions the Scheme of Arrangement, the companies anticipate the business combination will be consummated on or about December 1, 2026.
ARC Group Securities Acquisition I Nasdaq/NYSE Compliance Notice
ARC Group Securities Acquisition I received a deficiency notice from Nasdaq because the aggregate market value of its outstanding warrants fell below the $1 million minimum requirement. The company has until December 4, 2026, to submit a plan to regain compliance, which could grant an extension until April 18, 2027. This notice currently only affects the listing of the warrants (FJDIW) and not the company's ordinary shares or units.
Energy Services of America Signs $6.95M M&A Deal with FAMCO, Inc.
Energy Services of America Corporation completed the acquisition of substantially all operating assets of FAMCO, Inc., a West Virginia utility contractor focused on water and sewer infrastructure. The base purchase price was $6.95 million, paid through a combination of cash and Energy Services common stock. The deal expands the company's capabilities and workforce in the water and utility construction markets.
Allegiant Travel Company exercised options to purchase six additional Boeing 737-8 aircraft scheduled for delivery in 2028, bringing its total firm orders to 56 aircraft. The list price for the six aircraft exceeds $720 million, though final prices are subject to discounts and escalations. Additionally, the company entered into new multi-year employment agreements with its executive leadership team, including CEO Gregory Anderson and President/CFO Robert Neal.
TCGX Acquisition Corp. II completed its initial public offering of 10,000,000 Class A ordinary shares and a simultaneous private placement of 450,000 shares to its sponsor. The combined transactions generated $104.5 million in gross proceeds, with $100 million placed into a trust account for the benefit of shareholders.
Southport Acquisition Corp. II Capital Raise of $210M
Southport Acquisition Corp. II reported the final results of its initial public offering (IPO), which generated $210 million in gross proceeds from the sale of 21,000,000 units. Following the partial exercise and subsequent expiration of the underwriters' over-allotment option, the company's sponsor forfeited 666,667 Class B ordinary shares.
XCF Global Signs $60M M&A Deal with Air Products Manufacturing LLC
XCF Global, through its subsidiary New Rise Renewables Paramount, LLC, has entered into a definitive agreement to acquire a sustainable aviation fuel (SAF) production facility in Paramount, California from Air Products Manufacturing LLC. The purchase price consists of $10 million in cash at closing plus a $50 million deferred payment due in 36 months. The acquisition adds approximately 50 million annual gallons of production capacity and is strategically located near Los Angeles International Airport.
Dragonfly Energy Holdings Nasdaq/NYSE Compliance Notice
Dragonfly Energy Holdings Corp. received an extension from Nasdaq until December 31, 2026, to regain compliance with the minimum stockholders' equity requirement of $2.5 million. The company had previously reported a stockholders' equity deficit of $184,000 for the period ended June 30, 2026. If the company fails to demonstrate compliance by the deadline, its common stock and warrants may be subject to delisting from The Nasdaq Capital Market.
Alaunos Therapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000 following a private placement financing. As a result, the previously scheduled delisting hearing has been cancelled and the company's common stock will continue to trade on The Nasdaq Capital Market.
Permian Basin Royalty Trust M&A Deal with PBT Land and Minerals, Inc.
Permian Basin Royalty Trust has received a request from SoftVest Advisors and other unit holders to call a special meeting on November 23, 2026, to vote on a proposed business combination. The meeting will consider an amendment to the Trust Indenture to effect the combination with PBT Land and Minerals, Inc. and the adoption of an omnibus incentive plan. The Trustee intends to call the meeting as requested by holders of more than 15% of the outstanding units.
House of Doge Signs $15M M&A Deal with McQueen Labs Inc.
House of Doge Inc. entered into a binding letter of intent to acquire the MCQ Markets technical and token platform and the McQueen microlending business from McQueen Labs Inc. for $15 million. The consideration includes common stock, a new series of non-voting convertible preferred stock, and a promissory note with milestone-contingent payments. Concurrently, the company is contributing certain assets to the newly formed Dogecoin Labs in exchange for a strategic equity stake.
Marketaxess Holdings M&A Deal with Intercontinental Exchange, Inc.
MarketAxess Holdings Inc. provided a status update on its pending merger with Intercontinental Exchange, Inc. (ICE), specifically addressing litigation and stockholder demands alleging incomplete disclosures in its proxy statement. To avoid potential delays to the transaction, the company has voluntarily issued supplemental disclosures to moot the legal claims ahead of the stockholder vote scheduled for October 29, 2026.
Century Casinos received a deficiency notice from Nasdaq because its Market Value of Listed Securities (MVLS) fell below the $35 million minimum requirement for 30 consecutive business days. The company has 180 calendar days, until April 19, 2027, to regain compliance by maintaining an MVLS of at least $35 million for 10 consecutive business days. The notice has no immediate effect on the listing of the company's common stock.
Evernorth Holdings Inc. entered into a Common Stock Purchase Agreement with CF Principal Investments LLC (Cantor) to establish a committed equity facility. The company has the right to sell up to 5,218,935 shares of Class A common stock to Cantor at 97% of the volume-weighted average price over a 14-month period.
Laser Photonics Corp received a deficiency notice from Nasdaq on October 20, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, until April 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days.